MARKET

DMPI

DMPI

DelMar Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5915
-0.0088
-1.46%
After Hours: 0.5900 -0.0015 -0.26% 16:34 12/13 EST
OPEN
0.6200
PREV CLOSE
0.6003
HIGH
0.6220
LOW
0.5800
VOLUME
85.73K
TURNOVER
--
52 WEEK HIGH
6.29
52 WEEK LOW
0.4020
MARKET CAP
6.75M
P/E (TTM)
-0.2358
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of DMPI and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

DMPI News

  • DelMar Pharmaceuticals to Present at the LD Micro 12th Annual Main Event on December 10, 2019
  • PR Newswire.12/03 13:30
  • /C O R R E C T I O N -- DelMar Pharmaceuticals, Inc./
  • PR Newswire.11/25 17:17
  • DelMar Pharma Highlights Presentation Of Interim Data Of VAL-083 Showing Favorable Outcomes In Both Recurrent, Newly-Diagnosed GBM
  • Benzinga.11/25 14:53
  • The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate
  • Benzinga.11/22 13:18

More

Industry

Holding Companies
-0.05%
Financials
-0.07%

Hot Stocks

Name
Price
%Change

About DMPI

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).
More

Webull offers DelMar Pharmaceuticals Inc (DMPI) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.